Renaissance Technologies’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Renaissance Technologies’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-300,745	Closed	-$14.4M	–	3956
2020 Q1	$14.4M	Sell	300,745 -66,100	-18%	-$3.07M	0.01%	943
2019 Q4	$17.2M	Buy	+366,845	New	+$16.2M	0.01%	1087
2019 Q2	–	Sell	-291,200	Closed	-$6.52M	–	3841
2019 Q1	$6.52M	Buy	291,200 +99,300	+52%	+$2.13M	0.01%	1638
2018 Q4	$3.49M	Buy	191,900 +46,100	+32%	+$724K	﹤0.01%	1955
2018 Q3	$2.64M	Buy	145,800 +78,300	+116%	+$928K	﹤0.01%	2150
2018 Q2	$672K	Sell	67,500 -110,000	-62%	-$760K	﹤0.01%	2743
2018 Q1	$943K	Buy	+177,500	New	+$1.27M	﹤0.01%	2682

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Renaissance Technologies's RARX Position: Q2 2020 in Review

Renaissance Technologies sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 300,745 shares — an estimated $14.4M sold.

Renaissance Technologies first reported a position in RARX in Q1 2018 and held it in 7 quarters. The position peaked at $17.2M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Renaissance Technologies reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Renaissance Technologies sold 300,745 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $14.4M.
Renaissance Technologies first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 7 quarters.
Renaissance Technologies's Ra Pharmaceuticals, Inc. Common Stock position peaked at $17.2M in Q4 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.